- Home
- REGN vs JCI Comparison
REGN vs JCI Comparison
Compare REGN & JCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | JCI |
|---|---|---|
| Founded | 1988 | 1885 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1B | 84.3B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | REGN | JCI |
|---|---|---|
| Price | $745.07 | $157.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 22 |
| Target Price | ★ $859.04 | $166.90 |
| AVG Volume (30 Days) | 597.3K | ★ 2.8M |
| Earning Date | 10-30-2026 | 10-27-2026 |
| Dividend Yield | 0.51% | ★ 1.04% |
| EPS Growth | 8.19 | ★ 99.60 |
| EPS | ★ 18.95 | 1.86 |
| Revenue | $5,872,227,000.00 | ★ $9,902,000,000.00 |
| Revenue This Year | $20.04 | $8.36 |
| Revenue Next Year | $7.66 | $8.14 |
| P/E Ratio | ★ $39.03 | $82.80 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $104.49 |
| 52 Week High | $859.34 | $160.41 |
Technical Indicators
Market Signals| Indicator | REGN | JCI |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 64.62 |
| Support Level | $732.04 | $136.10 |
| Resistance Level | $779.86 | N/A |
| Average True Range (ATR) | 20.37 | 3.10 |
| MACD | -3.45 | 0.97 |
| Stochastic Oscillator | 24.71 | 84.80 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About JCI Johnson Controls International plc
Following Johnson Controls' divestiture of its residential and light commercial HVAC businesses to Bosch in 2025, nearly all of its revenue comes from commercial HVAC (60%) and fire and security products and services (40%). A 2016 merger joined Johnson Controls' HVAC and Tyco's fire and security businesses with the premise that there is synergy in offering a broader variety of automation products and solutions to commercial buildings. We estimate Johnson Controls' pro forma revenue mix will be one-third products, one-third installation, and one-third services.